Summary
N-acetylcysteine (NAC) is a precursor of glutathione (GSH) synthesis, a free radical scavenger and an inhibitor of tumour necrosis factor α (TNF). Because these functions might be beneficial in diabetic complications, in this study we examined whether NAC inhibits peripheral neuropathy. Motor nerve conduction velocity (MNCV) was significantly decreased in streptozotocin-induced-diabetic Wistar rats compared to control rats. Oral administration of NAC reduced the decline of MNCV in diabetic rats. Structural analysis of the sural nerve disclosed significant reduction of fibres undergoing myelin wrinkling and inhibition of myelinated fibre atrophy in NAC-treated diabetic rats. NAC treatment had no effect on blood glucose levels or on the nerve glucose, sorbitol and cAMP contents, whereas it corrected the decreased GSH levels in erythrocytes, the increased lipid peroxide levels in plasma and the increased lipopolysaccharide-induced TNF activity in sera of diabetic rats. Thus, NAC inhibited the development of functional and structural abnormalities of the peripheral nerve in streptozotocin-induced diabetic rats.
Similar content being viewed by others
Abbreviations
- TNF:
-
Tumour necrosis factor α
- NAC:
-
N-acetylcysteine
- GSH:
-
glutathione
- STZ:
-
streptozotocin
- MNCV:
-
motor nerve conduction velocity
- LPS:
-
lipopolysaccharide
References
Boulton AJM (1993) Pathogenesis of diabetic neuropathy. In: Marshall SM, Home PD, Alberti KGMM, Krall LP (eds) The diabetes annual/7. Elsevier, Amsterdam, pp 192–210
Loven D, Schedl H, Wilson H et al. (1986) Effect of insulin and oral glutathione on glutathione levels and superoxide dismutase activities in organs of rats with streptozotocin-induced diabetes. Diabetes 35: 503–507
Tanaka S-I, Seino H, Satoh J et al. (1992) Increased in vivo production of tumor necrosis factor after development of diabetes in nontreated, long-term diabetic BB rats. Clin Immunol Immunopathol 62: 258–263
Sagara M, Satoh J, Zhu XP et al. (1994) Inhibition with N-acetylcysteine of enhanced production of tumor necrosis factor in streptozotocin-induced diabetic rats. Clin Immunol Immunopathol 71: 333–337
Beutler B, Cerami A (1987) Cachectin: more than a tumor necrosis factor. N Engl J Med 316: 379–385
Tracey KJ, Vlassara H, Cerami A (1989) Cachectin/tumour necrosis factor. Lancet I: 1122–1125
Editorial (1991) Acetylcysteine. Lancet 337: 1069–1070
Peristeris P, Clark BD, Gatti S et al. (1992) N-acetylcysteine and glutathione as inhibitors of tumor necrosis factor production. Cell Immunol 140: 390–399
Satoh J, Seino H, Abo T et al. (1989) Recombinant human tumor necrosis factor α suppresses autoimmune diabetes in nonobese diabetic mice. J Clin Invest 84: 1345–1348
Yagihashi S, Kamijo M, Ido Y, Mirrlees DJ (1990) Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy. Diabetes 39: 690–696
Ellman GL (1958) A colorimetric method for determining low concentrations of mercaptons. Arch Biochem Biophys 74: 443–450
Yagi K (1976) A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med 15: 212–216
Malone JI, Knox G, Benford S, Tedesco TA (1980) Red cell sorbitol: an indicator of diabetic control. Diabetes 29: 861–864
Honma M, Satoh T, Takezawa J, Ui M (1977) An ultrasensitive method for the simultaneous determination of cyclic AMP and cyclic GMP in small-volume samples from blood and tissue. Biochem Med 18: 257–273
Dyck PJ, Karnes J, Lais A, Lofgren EP, Stevens JC (1984) Pathologic alterations of the peripheral nervous system of humans. In: Peripheral neuropathy. Dyck PJ, Thomas PK, Lambert EH, Bunge R (eds) Saunders, Philadelphia, pp 760–870
Yagihashi S, Kamijo M, Watanabe K (1990) Reduced myelinated fiber size correlates with loss of axonal neurofilaments in peripheral nerve of chronically streptozotocin diabetic rats. Am J Pathol 136: 1365–1373
Sima AAF, Zhang W-X, Tze WJ, Tai J, Nathaniel V (1988) Diabetic neuropathy in STZ-induced diabetic rat and effect of allogeneic islet cell transplantation. Diabetes 37: 1129–1136
Yasuda H, Sonobe M, Yamashita M et al. (1989) Effect of prostaglandin E1 analogue TFC612 on diabetic neuropathy in streptozocin-induced diabetic rats. Diabetes 38: 832–838
Burgunder JM, Varriale A, Lauterberg BH (1989) Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol 36: 127–131
Meister A, Anderson ME (1983) Glutathione. Ann Rev Biochem 52: 711–760
Murakami K, Kondo T, Ohtsuka Y, Fujiwara Y, Shimada M, Kawakami Y (1989) Impairment of glutathione metabolism in erythrocytes from patients with diabetes mellitus. Metabolism 38: 753–758
Lu CS, Ge J, Kuhlenkamp J, Kaplowitz N (1992) Insulin and glucocorticoid dependence of hepatic γ-glutamylcysteine synthetase and glutathione synthesis in the rat. J Clin Invest 90: 524–532
Hunt VJ, Dean RT, Wolff SP (1988) Hydroxyl radical production and autoxidative glycosylation. Biochem J 256: 205–212
Barnett PA, Gonzalez RG, Chylack LT, Chylack LT Jr, Cheng H-M (1986) The effect of oxidation on sorbitol pathway kinetics. Diabetes 35: 426–432
Brownlee M, Cerami A, Vlassara H (1988) Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease. Diab Metab Rev 4: 437–451
Romero FJ, Segura-Aguilar J, Monsalve E et al. (1990) Antioxidant and glutathione-related enzymatic activities in rat sciatic nerve. Neurotoxicol Teratol 12: 603–605
Kashiwagi A, Asahina T, Ikebuchi M et al. (1994) Abnormal glutathione metabolism and increased cytotoxicity caused by H2O2 in human umbilical vein endothelial cells cultured in high glucose medium. Diabetologia 37: 264–269
Chaudhri G, Clark IA (1989) Reactive oxygen species facilitate the in vitro and in vivo lipopolysaccharide-induced release of tumor necrosis factor. J Immunol 143: 1290–1294
Cameron NE, Cotter MA, Maxfield EK (1993) Anti-oxidant treatment prevents the development of peripheral nerve dysfunction in streptozotocin-diabetic rats. Diabetologia 36: 299–304
Bravenboer B, Kappelle AC, Hamers FPT, Van Buren T, Erkelens DW, Gispen WH (1992) Potential use of glutathione for prevention and treatment of diabetic neuropathy in the streptozotocin-induced diabetic rat. Diabetologia 35: 813–817
Low PA (1987) Recent advances in the pathogenesis of diabetic neuropathy. Muscle Nerve 10: 121–128
Spies JM, Westland KW, Hodgkinson SJ, Pollard JD (1994) Intraneuronal tumor necrosis factor causes focal breakdown of the blood nerve barrier. Proc Peripheral Nerve Society Meeting, St. Paul, June 12–16, pp 146 (Abstract)
Mayer M, Noble M (1994) N-Acetyl-L-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro. Proc Natl Acad Sci USA 91: 7496–7500
Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A (1988) Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 240: 1546–1548
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sagara, M., Satoh, J., Wada, R. et al. Inhibition of development of peripheral neuropathy in streptozotocin-induced diabetic rats with N-acetylcysteine. Diabetologia 39, 263–269 (1996). https://doi.org/10.1007/BF00418340
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00418340